| Field | Specification |
|---|---|
| Target | |
| Alternative names | VEGFA; VEGF; Vascular endothelial growth factor A; VEGF-A; Vascular permeability factor; VPF |
| Gene ID | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | The antiserum was produced against synthesized peptide derived from human VEGF-A. AA range:110-159 |
| Conjugate | |
| Concentration | |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Scientific Background
This gene is a member of the PDGF/VEGF growth factor family. It encodes a heparin-binding protein, which exists as a disulfide-linked homodimer. This growth factor induces proliferation and migration of vascular endothelial cells, and is essential for both physiological and pathological angiogenesis. Disruption of this gene in mice resulted in abnormal embryonic blood vessel formation. This gene is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Elevated levels of this protein are found in patients with POEMS syndrome, also known as Crow-Fukase syndrome. Allelic variants of this gene have been associated with microvascular complications of diabetes 1 (MVCD1) and atherosclerosis. Alternatively spliced transcript variants encoding different isoforms have been described. There is also evidence for alternative translation initiation fro
Product Overview
This polyclonal antibody, raised in Rabbit, recognizes VEGF-A. It is validated for Western Blot, Immunofluorescence, Immunohistochemistry, ELISA.
Validated Applications
| Applications | Western Blot, Immunofluorescence, Immunohistochemistry, ELISA |
|---|---|
| Western Blot | 1/500 - 1/2000.IF: 1:50-200 Immunohistochemistry: 1/100 - 1/300. ELISA: 1/10000. Not yet tested in other applications. |
Optimal dilutions should be determined by the end user for each application and sample type.
Immunogen
The antiserum was produced against synthesized peptide derived from human VEGF-A. AA range:110-159
Specifications
| Host | Rabbit |
|---|---|
| Clonality | Polyclonal |
| Isotype | IgG |
| Conjugate | Unconjugated |
| Reactivity | Human, Mouse, Rat, Pig, Rabbit |
| Immunogen | The antiserum was produced against synthesized peptide derived from human VEGF-A. AA range:110-159 |
| Concentration | 1 mg/mL |
| Observed Band | 21kD(monomer),42kD(dimer) |
| Subcellular Location | Secreted . VEGF121 is acidic and freely secreted. VEGF165 is more basic, has heparin-binding properties and, although a significant proportion remains cell-associated, most is freely secreted. VEGF189 is very basic, it is cell-associated after secretion and is bound avidly by heparin and the extracellular matrix, although it may be released as a soluble form by heparin, heparinase or plasmin. |
| Swiss-Prot | P15692 |
| Gene ID | 7422 |
| Storage | -20°C/1 year |
Reactivity Notes
Validated reactivity: Human, Mouse, Rat, Pig, Rabbit. For other species, epitope conservation may allow cross-reactivity; confirm with appropriate controls.
Safety & Handling
This product is for research use only (RUO) and is not intended for diagnostic or therapeutic use. The formulation contains sodium azide; handle with standard laboratory precautions.
Related Products
Explore related antibodies and reagents for VEGF-A research from ELK Biotechnology, or contact us for alternative formats.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
